✨ Free AI Report
Telix Pharmaceuticals Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Telix Pharmaceuticals Limited
Company Research

Telix Pharmaceuticals Limited: Business Overview, Financials & Competitive Analysis

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. In February 2026, Telix reported full-year ...

Analyst-debate audio for Telix Pharmaceuticals Limited

AskCyborg analysts argue the bull and bear cases for Telix Pharmaceuticals Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Telix demonstrates strong commercial momentum with profitable core products, but execution risk and regulatory uncertainty create...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Radiopharmaceuticals / Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Telix Pharmaceuticals Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Telix Pharmaceuticals Limited Overview

Pro stress-test →

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. In February 2026, Telix reported full-year 2025 sales of US$803.79 million alongside a small net loss of US$7.13 million, with 2026 revenue guidance of US$950 million to US$970 million. The company is scaling its commercial footprint while expanding its radiopharmaceutical pipeline beyond prostate imaging into oncology therapeutics.

Strategic Profile

Pro stress-test →

Telix is coupling higher revenue ambitions and capital-raising flexibility with efforts to broaden its oncology imaging portfolio into glioma, including use alongside its TLX101-Tx therapy program. The 2026 revenue guidance embeds a full year of contribution from the lower margin RLS network, while still leaning on Illuccix and Gozellix to carry the topline. However, the company faces near-term regulatory headwinds including SEC scrutiny and recent FDA rejections for pipeline candidates.

Competitive Landscape

Pro stress-test →

To own Telix, you need to believe it can turn a growing radiopharmaceutical imaging franchise into a broader oncology platform while managing heavy reinvestment and regulatory complexity. Telix competes in the specialized radiopharmaceutical space with established diagnostic imaging revenue but faces competitive pressure in PSMA imaging. The company's differentiation lies in its vertically integrated manufacturing (RLS acquisition) and dual theranostic platform approach.

Industry Context

Telix Pharmaceuticals Limited operates in Biopharmaceutical - Radiopharmaceuticals / Oncology.

Key facts

Founded: 2015 · Headquarters: Melbourne, Australia · Revenue: $803.8M USD (2025) · Market cap: $3.31B AUD

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Telix Pharmaceuticals Limited.

  • Medicare reimbursement for Gozellix driving U.S. market penetration and sustainable growth
  • FDA rejected marketing applications for both Pixclara and TLX250-CDx, two products the company had anticipated would contribute to near-term revenue growth
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026FY2025 results: US$803.8M revenue (+56% YoY), issued 2026 guidance of US$950-970M
  • February 2026Submitted European marketing authorization application for TLX101-Px glioma imaging agent
  • +2 moreTrack every material event for Telix Pharmaceuticals Limited as it happens. Explore monitoring →
Get alerted when Telix Pharmaceuticals Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

PSMA imaging agentsCompeting prostate cancer diagnostic imaging solutions→Therapeutic radiopharmaceuticalsTargeted cancer therapy platforms→PET imaging diagnosticsRadiopharmaceutical diagnostic imaging→

Compare Telix Pharmaceuticals Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Telix Pharmaceuticals Limited operates in Biopharmaceutical - Radiopharmaceuticals / Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Radiopharmaceuticals / Oncology research →
NEW · MCP server

Ask your AI assistant about Telix Pharmaceuticals Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Telix Pharmaceuticals Limited and its top competitor on Cyborg Score”
“What did Telix Pharmaceuticals Limited do this quarter?”
“Is Telix Pharmaceuticals Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Telix Pharmaceuticals Limited do?+
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. In February 2026, Telix reported full-year ...
What is Telix Pharmaceuticals Limited's Cyborg Score?+
Telix Pharmaceuticals Limited has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Telix Pharmaceuticals Limited's main competitors?+
Named competitors include PSMA imaging agents, Therapeutic radiopharmaceuticals, PET imaging diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Telix Pharmaceuticals Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Telix Pharmaceuticals Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Telix Pharmaceuticals Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.